Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3OU54)

Drug Name
ICI 118,551 Drug Info
Synonyms
Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO
Indication
Disease Entry ICD 11 Status REF
Gastric adenocarcinoma 2B72 Phase 3 [1]
HER2-positive breast cancer 2C60-2C65 Phase 3 [2]
Cross-matching ID
PubChem CID
3682
ChEBI ID
CHEBI:91879
TTD Drug ID
DM3OU54

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Adrenergic receptor beta-2 (ADRB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indacaterol DMQJHR7 Chronic obstructive pulmonary disease CA22 Approved [7]
Formoterol DMSOURV Allergic asthma CA23.0 Approved [8]
Salbutamol DMN9CWF Acute asthma CA23 Approved [9]
Arformoterol DMYM974 Chronic obstructive pulmonary disease CA22 Approved [10]
Isoproterenol DMK7MEY Atrioventricular block Approved [11]
Salmeterol DMIEU69 Allergic asthma CA23.0 Approved [12]
Clenbuterol DMCKYZ5 Chronic breathing disorder 7A4Z Approved [13]
Ritodrine DM4V6RL Premature labour JB00 Approved [14]
Olodaterol DM62B78 Chronic obstructive pulmonary disease CA22 Approved [15]
Fenoterol DMIP3ZV Asthma CA23 Approved [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 72 kDa type IV collagenase (MMP2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [17]
Selenium DM25CGV N. A. N. A. Approved [18]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [19]
Quercetin DM3NC4M Obesity 5B81 Approved [20]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [21]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [22]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [23]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [24]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [25]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [26]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Matrix metalloproteinase-9 (MMP9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [27]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [28]
Gefitinib DM15F0X Colon adenocarcinoma Approved [29]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [30]
Selenium DM25CGV N. A. N. A. Approved [18]
Pentosan Polysulfate DM2HRKE Interstitial cystitis GC00.3 Approved [31]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [32]
Methotrexate DM2TEOL Anterior urethra cancer Approved [33]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [34]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [35]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prostaglandin G/H synthase 2 (PTGS2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [36]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [37]
Gamolenic acid DMQN30Z Allergy 4A80-4A85 Approved [38]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [39]
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [40]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [41]
Ibandronate DM0QZBN Hypercalcaemia 5B91.0 Approved [42]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [28]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [43]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Beta-2 adrenergic receptor (ADRB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salmeterol DMIEU69 Allergic asthma CA23.0 Approved [45]
Bambuterol DMKLSHF Asthma CA23 Approved [46]
Terbutaline DMD4381 Asthma CA23 Approved [47]
Salbutamol DMN9CWF Acute asthma CA23 Approved [48]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [49]
Methotrexate DM2TEOL Anterior urethra cancer Approved [50]
Epinephrine DM3KJBC Acute asthma CA23 Approved [51]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [52]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [53]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metoclopramide DMFA5MY Nausea MD90 Approved [55]
Quinidine DMLPICK N. A. N. A. Approved [56]
Verapamil DMA7PEW Angina pectoris BA40 Approved [57]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [58]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [58]
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [59]
Propranolol DM79NTF Angina pectoris BA40 Approved [6]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [60]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [61]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [58]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Antagonist [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Gene/Protein Processing [4]
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Protein Interaction/Cellular Processes [5]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Gene/Protein Processing [4]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [6]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Gene/Protein Processing [4]
Vascular endothelial growth factor A, long form OTIM9MZ3 VEGFA_HUMAN Gene/Protein Processing [4]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Selective beta 2-adrenoceptor antagonists: derivatives of ICI 118,551 and a binary aryloxypropanolamine. J Pharm Pharmacol. 1988 Nov;40(11):803-5.
4 beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFB and AP-1. Cancer Biol Ther. 2010 Jul 1;10(1):19-29.
5 Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther. 1999 Apr;13(2):123-6. doi: 10.1023/a:1007784109255.
6 Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
7 Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
8 Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
9 Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
10 Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
11 Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
12 Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
13 Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
15 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
16 Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.
17 Oxidative Stress-Protective and Anti-Melanogenic Effects of Loliolide and Ethanol Extract from Fresh Water Green Algae, Prasiola japonica. Int J Mol Sci. 2018 Sep 18;19(9):2825. doi: 10.3390/ijms19092825.
18 Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
19 Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Hum Reprod. 2007 Apr;22(4):1161-7. doi: 10.1093/humrep/del464. Epub 2006 Dec 11.
20 Quercetin Suppresses the Migration and Invasion in Human Colon Cancer Caco-2 Cells Through Regulating Toll-like Receptor 4/Nuclear Factor-kappa B Pathway. Pharmacogn Mag. 2016 May;12(Suppl 2):S237-44. doi: 10.4103/0973-1296.182154. Epub 2016 May 11.
21 Troglitazone but not conjugated linoleic acid reduces gene expression and activity of matrix-metalloproteinases-2 and -9 in PMA-differentiated THP-1 macrophages. J Nutr Biochem. 2008 Sep;19(9):594-603. doi: 10.1016/j.jnutbio.2007.08.003. Epub 2007 Dec 21.
22 Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
23 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
24 Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J Cell Biochem. 2005 Aug 1;95(5):955-69. doi: 10.1002/jcb.20452.
25 Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology. 2009;83(1):18-25. doi: 10.1159/000166183. Epub 2008 Oct 30.
26 Repetitive nonlethal oxidant injury to retinal pigment epithelium decreased extracellular matrix turnover in vitro and induced sub-RPE deposits in vivo. Invest Ophthalmol Vis Sci. 2006 Sep;47(9):4098-112. doi: 10.1167/iovs.05-1230.
27 Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment. Pharmaceutics. 2021 Sep 7;13(9):1415. doi: 10.3390/pharmaceutics13091415.
28 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
29 Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
30 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
31 Pentosan polysulfate decreases proliferation and extracellular matrix deposition by vascular smooth muscle cells isolated from failed hemodialysis access grafts. Clin Nephrol. 2000 Aug;54(2):121-7.
32 Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
33 Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
34 Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide. PLoS One. 2014 Jun 23;9(6):e99993. doi: 10.1371/journal.pone.0099993. eCollection 2014.
35 Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci. 2004 Apr;94(4):403-9. doi: 10.1254/jphs.94.403.
36 Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicol Lett. 2015 Jul 16;236(2):75-81.
37 Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
38 Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006 Nov;96(5):811-9.
39 COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
40 Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
41 Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
42 Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
43 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
44 A2E selectively induces cox-2 in ARPE-19 and human neural cells. Curr Eye Res. 2006 Mar;31(3):259-63.
45 Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007 Feb;36(2):236-43. doi: 10.1165/rcmb.2006-0257OC. Epub 2006 Sep 15.
46 Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via (2)-adrenoceptor. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30.
47 Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. doi: 10.1097/01.pcc.0000194010.63115.a2.
48 beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005 Apr;90(4):2301-7. doi: 10.1210/jc.2004-1356. Epub 2005 Feb 1.
49 Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol. 1999 Dec 15;386(2-3):135-44. doi: 10.1016/s0014-2999(99)00749-9.
50 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
51 Myocardial ischaemia and ventricular arrhthymias precipitated by physiological concentrations of adrenaline in patients with coronary artery disease. Br Heart J. 1992 May;67(5):419-20. doi: 10.1136/hrt.67.5.419-b.
52 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
53 Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.
54 Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors. Biochem Pharmacol. 2007 Mar 15;73(6):814-23. doi: 10.1016/j.bcp.2006.11.022. Epub 2006 Dec 1.
55 Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
56 Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
57 Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
58 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
59 Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
60 Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
61 Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.